Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results

Data Visualizations

Phase Distribution

3Total
Early P 1 (1)
P 3 (2)

Trial Status

Unknown2
Not Yet Recruiting1
Active Not Recruiting1

Clinical Trials (4)

Showing 4 of 4 trials
NCT05288166Phase 3Active Not Recruiting

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

NCT06768255Phase 3Not Yet RecruitingPrimary

Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPC

NCT04735913Early Phase 1UnknownPrimary

Effects of Metabolic Enzymes and Transporter Gene Polymorphisms on the Pharmacokinetics and Metabolism of Oral Abiraterone Acetate in Healthy Chinese Adults

NCT02787837Unknown

PROSABI: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Abiraterone Acetate.

Showing all 4 trials

Research Network

Activity Timeline